Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world safety and effectiveness study of AK-HER2 in HER2-positive cancers
ChiCTR2400084071Phase 4Not yet recruiting
- Sponsor
- Changhai Hospital
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of trastuzumab in breast cancer, gastric cancer (GC) and Non-hematologic malignancy (3 cohorts), sponsored by Changhai Hospital. Primary endpoint: Safety evaluation. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
03
Conditions
breast cancergastric cancer (GC)Non-hematologic malignancy
Beyond the preview
Go deeper on ChiCTR2400084071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084071.